CHARACTERISTICS OF AND RISK-FACTORS FOR RELAPSE OF BRUCELLOSIS IN HUMANS

被引:136
作者
ARIZA, J
CORREDOIRA, J
PALLARES, R
VILADRICH, PF
RUFI, G
PUJOL, M
GUDIOL, F
机构
[1] Infectious Disease Service, Hospital de Bellvitge, Universidad de Barcelona, Barcelona
关键词
D O I
10.1093/clinids/20.5.1241
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
For 16 years we prospectively observed 530 adult patients with brucellosis to analyze the characteristics of and risk factors for relapse, Clinical and laboratory findings from 86 relapsed patients were milder during the relapse episode when compared with those for the same patients during the initial disease, Blood cultures were positive for Brucella melitensis in 65% of cases during relapse and in similar to 80% of cases during the initial disease. Risk factors that were identified as being independently associated with relapse (by logistic regression analysis) were ''less-effective'' antibiotic therapy (OR, 8.3; 95% CI, 4.6-15.1), positive blood cultures during initial disease (OR, 2.7; 95% CI, 1.2-6.2), less than or equal to 10-day duration of the disease before treatment (OR, 1.9; 95% CI, 1.1-3.6), male sex (OR, 1.8; 95% CI, 1.02-3.8), and a platelet count of less than or equal to 150 X 10(3)/mm(3) (OR, 1,7; 95% CI, 1.1-2.8), These data show that relapse of brucellosis is sometimes difficult to diagnose and that it can be an insidious disease. In addition to inappropriate antibiotic therapy, other factors, such as those indicating a more aggressive disease and/or a deficient immunologic response, seem to play an important role in the relapse of brucellosis.
引用
收藏
页码:1241 / 1249
页数:9
相关论文
共 64 条
[11]  
Young E.J., Borchert M., Kretzer E.L., Musher D.M., Phagocytosis and killing of, J Infect Dis, 151, pp. 682-690, (1985)
[12]  
Gotuzzo E., Bocanegra T.S., Alarcon G.S., Carrillo C., Espinoza L.R., Humoral immune abnormalities in human brucellosis, Allergol Immunopathol (Madr), 13, pp. 417-424, (1985)
[13]  
Canning P.C., Roth J.A., Deyoe B.L., Release of 5'-guanosine monophos phate and adenine by, J Infect Dis, 154, pp. 464-470, (1986)
[14]  
Plommet M., Brucellosis and immunity: Humoral and cellular compo nents in mice, Ann Inst Pasteur Microbiol, 138, pp. 105-110, (1987)
[15]  
Bosseray N., Plommet M., Serum- and cell-mediated immune protection of mouse placenta and fetus against, Placenta, 9, pp. 65-79, (1988)
[16]  
Smith L.D., Ficht T.A., Pathogenesis of, Crit Rev Microbiol, 17, pp. 209-230, (1990)
[17]  
Janbon M., Bertrand L., Premiere experience du traitement de la brucel- lose a, Bull Et Mem Soc Med Hop Paris, 66, pp. 1352-1360, (1950)
[18]  
Pedro-Pons A., Pedro-Botet J., Resultados obtenidos con et tratamiento aureomicinico de la fiebre de Malta, Med Clin (Bare), 16, pp. 232-243, (1951)
[19]  
Ruiz-Castaneda M., Guerrero Ibarra G., Terramycin in the treatment of human brucellosis, Antibiot Chemother, 2, pp. 86-90, (1952)
[20]  
Magill G.B., Killough J.H., Oxytetracycline-streptomycin therapy in bru cellosis due to, Arch Intern Med, (1953)